BACKGROUND: Although current left ventricular assist device (LVAD) technology has proven more durable than first-generation devices, all mechanical devices are prone to complications that can elevate patient acuity before transplantation. LVAD patients with complications intuitively carry a higher risk profile than other status 1A LVAD patients who are generally stable and use their 30 days of clinically stable status 1A time. We sought to determine if the presence or absence of complications in status 1A LVAD patients at the time of transplant influenced survival after transplant. METHODS: The United Network of Organ Sharing database was retrospectively analyzed for 15,253 patients who were listed status 1A from 1998 to 2008. Survival after transplant survival was compared between patients who were and were not listed for LVAD-related complications. Standard statistical analysis was applied. RESULTS: No survival difference was identified at 1 and 10 years after transplant in patients who had device complications compared with those without complications. Of the five complication entries (thromboembolism, infection, malfunction, malignant arrhythmia, and other), only device infection increased mortality risk compared with noncomplicated patients (39% at 1 year, 30% at 10 years, p < 0.01). CONCLUSIONS: Long-term outcomes are generally not affected by the status 1A listing criteria for patients bridged to transplant with LVADs. However, the subset of patients with device infection had worse 1-year and 10-year posttransplant survival. Bridge to transplant patients, despite serious device-related complications, still have excellent transplant outcomes.
BACKGROUND: Although current left ventricular assist device (LVAD) technology has proven more durable than first-generation devices, all mechanical devices are prone to complications that can elevate patient acuity before transplantation. LVAD patients with complications intuitively carry a higher risk profile than other status 1A LVAD patients who are generally stable and use their 30 days of clinically stable status 1A time. We sought to determine if the presence or absence of complications in status 1A LVAD patients at the time of transplant influenced survival after transplant. METHODS: The United Network of Organ Sharing database was retrospectively analyzed for 15,253 patients who were listed status 1A from 1998 to 2008. Survival after transplant survival was compared between patients who were and were not listed for LVAD-related complications. Standard statistical analysis was applied. RESULTS: No survival difference was identified at 1 and 10 years after transplant in patients who had device complications compared with those without complications. Of the five complication entries (thromboembolism, infection, malfunction, malignant arrhythmia, and other), only device infection increased mortality risk compared with noncomplicated patients (39% at 1 year, 30% at 10 years, p < 0.01). CONCLUSIONS: Long-term outcomes are generally not affected by the status 1A listing criteria for patients bridged to transplant with LVADs. However, the subset of patients with device infection had worse 1-year and 10-year posttransplant survival. Bridge to transplant patients, despite serious device-related complications, still have excellent transplant outcomes.
Authors: Kevin J Clerkin; Arthur Reshad Garan; Brian Wayda; Raymond C Givens; Melana Yuzefpolskaya; Shunichi Nakagawa; Koji Takeda; Hiroo Takayama; Yoshifumi Naka; Donna M Mancini; Paolo C Colombo; Veli K Topkara Journal: Circ Heart Fail Date: 2016-10 Impact factor: 8.790
Authors: Curtis J Wozniak; Josef Stehlik; Bradley C Baird; Stephen H McKellar; Howard K Song; Stavros G Drakos; Craig H Selzman Journal: Ann Thorac Surg Date: 2014-01-11 Impact factor: 4.330
Authors: Kevin J Clerkin; Yoshifumi Naka; Donna M Mancini; Paolo C Colombo; Veli K Topkara Journal: JACC Heart Fail Date: 2016-09-07 Impact factor: 12.035
Authors: Delphine Héquet; Georg Kralidis; Thierry Carrel; Alexia Cusini; Christian Garzoni; Roger Hullin; Pascal R Meylan; Paul Mohacsi; Nicolas J Mueller; Frank Ruschitzka; Piergiorgio Tozzi; Christian van Delden; Maja Weisser; Markus J Wilhelm; Manuel Pascual; Oriol Manuel Journal: BMC Infect Dis Date: 2016-07-08 Impact factor: 3.090
Authors: Radoslav Zinoviev; Christopher K Lippincott; Sara C Keller; Nisha A Gilotra Journal: Open Forum Infect Dis Date: 2020-04-17 Impact factor: 3.835